PMCB stock gains on $10M share buyback program (NASDAQ:PMCB)
seekingalpha.com
finance
2022-06-02 13:23:41

Melpomenem/iStock via Getty Images PharmaCyte Biotech (NASDAQ:PMCB), a nano-cap biotech focused on cellular therapies, said on Thursday that its board of directors authorized a share repurchase program to buy back up to $10M worth of shares of the company's outstanding common stock. The program takes effect immediately for a two-year period, with PharmaCyte (PMCB) planning to fund the program with its available cash. The decision to implement a buyback program was taken up at a quarterly board meeting in March, PharmaCyte's (PMCB) Chief Executive Kenneth L.
